(Q35170232)

6 August 2017

title

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study (English)

1 reference

6 August 2017

0 references

adrenocortical carcinoma

1 reference

15

Toni K Choueiri

1 reference

6 August 2017

12

F Stephen Hodi

1 reference

6 August 2017

13

Gordon J Freeman

1 reference

6 August 2017

2

Sabina Signoretti

1 reference

6 August 2017

André P Fay

1

1 reference

6 August 2017

Marcella Callea

3

1 reference

6 August 2017

Gabriela H Telό

4

1 reference

6 August 2017

Rana R McKay

5

1 reference

6 August 2017

Jiaxi Song

6

1 reference

6 August 2017

Ingrid Carvo

7

1 reference

6 August 2017

Megan E Lampron

8

1 reference

6 August 2017

Marina D Kaymakcalan

9

1 reference

6 August 2017

Carlos E Poli-de-Figueiredo

10

1 reference

6 August 2017

Joaquim Bellmunt

11

1 reference

6 August 2017

Aymen Elfiky

14

1 reference

6 August 2017

publication date

17 February 2015

1 reference

Journal for Immunotherapy of Cancer

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

page(s)

3

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

17 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s40425-015-0047-3

0 references

cites work

PD-L1 expression in nonclear-cell renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Adrenocortical carcinoma: the management of metastatic disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

PD-1 as a potential target in cancer therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Nivolumab plus ipilimumab in advanced melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

The PD-1 pathway in tolerance and autoimmunity

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Tumour immunity: effector response to tumour and role of the microenvironment

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Significance of B7-H1 overexpression in kidney cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

A clinical and pathological study of adrenocortical carcinoma: therapeutic implications

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Adrenal adenocarcinomas: histologic grading and survival

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Combination chemotherapy in advanced adrenocortical carcinoma.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Inflammatory cell distribution within and along asthmatic airways

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4357210

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

27 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS40425-015-0047-3

Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up

21 January 2018

1 reference

12 December 2020

Third national cancer survey: incidence data

1 reference

12 December 2020

Prognostic parameters of metastatic adrenocortical carcinoma

1 reference

12 December 2020

Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors

1 reference

12 December 2020

10.1186/S40425-015-0047-3

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference

6 August 2017

1 reference